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Keywords: Mcl-1; NSCLC; Bcl-x L Non-small-cell lung cancer (NSCLC) accounts for more than 80% of lung cancers and is the number one cause of cancer death in the United States and worldwide. Several mutations associated with this disease have been identified (Minna et al., 2002) . For example, mutations in the K-ras proto-oncogene are found in 15-20% of NSCLC (Rodenhuis and Slebos, 1992) . In addition, mutations and amplifications of the epidermal growth factor receptor are also very common in NSCLC (Linardou et al., 2009) . These mutations provide the basis for the development of targeted therapies for this subtype of cancer (Sun et al., 2007) . Although improved therapy is available, the median survival of late-stage disease is less than 1 year. Thus, new therapies are needed to improve the survival of NSCLC patients.
A hallmark of cancer cells is defects in the apoptotic cell death program (Hanahan and Weinberg, 2000) . Apoptosis is a highly regulated cell suicide process that functions to remove unwanted cells. One means of inhibiting the apoptotic pathway is through upregulation of the anti-apoptotic B-cell lymphoma 2 (Bcl-2) family members (Cory et al., 2003) . These proteins belong to a family of BH-domain-containing proteins (Reed et al., 2004) . There are three classes of BHdomain-containing proteins: (1) multidomain antiapoptotic (Bcl-2, Bcl-x L , Bcl-w, Bfl-1/A1 and Mcl-1), (2) multidomain proapoptotic (Bax and Bak) and (3) BH3-only proapoptotic (Bid, Bim, Bad, Bik, Noxa, Puma, Bmf and Hrk). The BH3-only proteins contain a single BH3 domain that interacts with specific antiapoptotic proteins . For example, Bcl-2 and Bcl-x L bind and antagonize Bad but not Noxa. In contrast, Mcl-1 and A1 bind and antagonize Noxa but not Bad protein. Other BH3 domain proteins such as Bim and Puma are bound and antagonized by all antiapoptotic proteins. Bax and Bak are the 'effectors'. Once activated, they form complexes and permeabilize the outer mitochondrial membrane, resulting in the release of cytochrome c and other pro-apoptogenic proteins to induce the cell death pathway. Currently, there are two models for activation of Bak/Bax. The direct activation model suggests that Bim, truncated Bid, and perhaps Puma can directly activate Bak and Bax (Letai et al., 2002) . These BH3-only proteins are called activators. The indirect model suggests that Bak and Bax are suppressed by the multidomain antiapoptotic proteins. Binding of the anti-apoptotic proteins by the BH3-only proteins causes the activation of Bak or Bax (Willis et al., 2007) .
Expression of Bcl-2 family members has been reported in both NSCLC patient tissues and NSCLC cell lines (Borner et al., 1999; Berrieman et al., 2005 (Wesarg et al., 2007) and in 58% of the specimens of patients with radically resected NSCLC (Borner et al., 1999) . Protein expression analysis of several NSCLC cell lines also demonstrated the presence of Mcl-1 (Song et al., 2005 ). Second, the high level of Mcl-1 in a NSCLC cell line H1299 results in resistance to ABT-737, a specific inhibitor of Bcl-2 and Bcl-x L but not Mcl-1. This resistance can be overcome by expressing Noxa to neutralize the effect of Mcl-1 (Wesarg et al., 2007) . Third, modest cell killing was observed when antisense Mcl-1 oligonucleotide was introduced into A549 and H1299 (Borner et al., 1999) . In this study, we sought to investigate the role of Bcl-2 family members in NSCLC cell lines systematically.
We first determined the protein expression of these Bcl-2 members in NSCLC cell lines. We collected cell lysates from 14 NSCLC cell lines and performed western blotting analysis (Figure 1a ). We found that almost all NSCLC cell lines have high levels of Mcl-1 expression, whereas Bcl-x L expression varies among these lines (Figure 1a ). Low Bcl-2 expression was detected in only two NSCLC lines (data not shown), consistent with other studies (Li et al., 2008) . Our data indicated that Mcl-1 and Bcl-x L might have important roles in NSCLC.
To determine the role of Mcl-1 and Bcl-x L in NSCLC cell lines, we silenced their expression by using small interfering RNA (siRNA) oligonucleotides specific to Mcl-1 and Bcl-x L , respectively. Two Mcl-1 siRNAs and Bcl-x L siRNA effectively knocked down Mcl-1 and Bcl-x L protein expression in H1299 cells (Figure 1b) . Viability of 14 NSCLC cell lines was assessed after transfecting Mcl-1 siRNA or Bcl-x L siRNA alone or in combination. Greater than 50% growth inhibition was observed in four NSCLC cell lines (H23, H1568, H522 and H838) after 2 days of transfection with Mcl-1 siRNA ( Figure 1c ). There was minimal or modest effect on the viability of other NSCLC cell lines. In contrast, silencing the expression of Bcl-x L or Bcl-2 had no effect on these NSCLC lines ( Figure 1c and data not shown). Interestingly, the viability of many lines was greatly reduced (H358, H1299, H2405, HCC827 and H1975) when Mcl-1 and Bcl-x L siRNAs were combined. Our data indicated that, although Mcl-1 is crucial for the survival of some NSCLC cell lines, most NSCLC cell lines utilize both Bcl-x L and Mcl-1 for survival. 
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It is interesting to note that the Mcl-1-dependent lines have higher protein expression of Mcl-1 than Bcl-x L . In order to determine whether this Mcl-1 dependency could be predicted at the messenger RNA (mRNA) level, we measured the mRNA levels of MCL1 and BCL-xl using quantitative real-time PCR assays. As expected, the ratio of MCL1 to BCL-xl mRNA expression is inversely correlated (À0.75) with the dependency of these lines on Mcl-1 (as determined by Mcl-1 knockdown; Figure 1d ).
H23 cells were found to have the most dramatic response when Mcl-1 was silenced, and so we used this cell line to further investigate the role of Mcl-1 in NSCLC. First, we determined the Mcl-1 dependence of H23 cells. Viability of H23 cells was assessed after transfection with increasing concentrations of control or Mcl-1 siRNA for 48 h. H23 cells were killed at less than 1 nM concentration of Mcl-1 siRNA (Figure 2a) , confirming that Mcl-1 is a critical survival factor for H23 cells. To further assess the role of Bcl-2 anti-apoptotic proteins in H23 cells, we evaluated the effect of transfecting Bcl-2, Bcl-x L and two Mcl-1 siRNAs, one targeting the coding sequence (CDS) and one targeting the 3 0 untranslated region of MCL1 (Mcl-1 3 0 UTR). Cell viability was measured using CellTiter-Glo assay and cell death was quantified by the release of adenylate kinase into cell culture medium from damaged cells. Only transfection of the two Mcl-1 siRNAs led to H23 cell death (Figures 2b and c) . Both Mcl-1 siRNAs effectively knocked down Mcl-1 protein expression (data not shown), suggesting that the cell killing is Mcl-1 specific. Transfection of Bcl-x L siRNA had no effect on H23 cell viability and cell death despite Mcl-1 in NSCLC cell lines H Zhang et al effective silencing of Bcl-x L protein in these cells (Figures 2b and c) . Similarly, Bcl-2 siRNA had no effect on cell viability or cell death (Figures 2b and c) , possibly because of undetectable Bcl-2 protein expression in these cells (data not shown). We also determined whether apoptosis was induced with Mcl-1 siRNAs by measuring adenylate kinase activity in the presence or absence of 50 mM caspase 3/7 inhibitor DEVE-fmk. Adenylate kinase activity was strongly increased upon Mcl-1 silencing with both Mcl-1 siRNAs, but was completely blocked by co-treatment with caspase 3/7 inhibitor (Figure 2d ). These data support the view that H23 cells utilize Mcl-1 to resist apoptosis.
An independent method was used to validate these findings. Clonogenic survival assay was performed in H23 cells following transfection with two control, Bcl-x L or Mcl-1 siRNAs. Consistent with the viability data, colony formation was significantly reduced with Mcl-1 siRNA as compared with control and Bcl-x L siRNAs (Figure 2e ).
To ascertain whether Mcl-1 is specific and crucial for H23 cell survival, we expressed a complementary DNA containing only the CDS of MCL1 with a Flag tag to perform rescue experiments in these cells. As shown in Figure 3a , viability of control vector-transfected H23 cells was greatly reduced by Mcl-1 siRNAs targeting the CDS or the 3 0 UTR. As expected, endogenous Mcl-1 was knocked down by both siRNAs (data not shown). In contrast, Mcl-1 siRNA targeting the 3 0 UTR had no effect on the viability of Flag-MCL1-transfected H23 cells, whereas viability was greatly reduced by Mcl-1 siRNA targeting the CDS (Figure 3a) . Immunoblotting showed that Mcl-1 CDS siRNA knocked down both endogenous and exogenous Mcl-1 in Flag-MCL1-transfected H23 cells (Figure 3b ). On the other hand, Mcl-1 siRNA targeting the 3 0 UTR knocked down endogenous Mcl-1 but had no effect on the exogenously expressed Flag-Mcl-1, as shown by western blotting using anti-Flag antibody (Figure 3b ). These data again confirm the essential role of Mcl-1 for H23 cell survival.
We next investigated how Mcl-1 prevents apoptosis in H23 cells. In the direct activation model, anti-apoptotic proteins oppose cell death by binding and sequestering BH3-only activators such as Bim, truncated Bid, and perhaps Puma to prevent their activation of effectors Bax and Bak. Immunoprecipitations with anti-Mcl-1 in H23 cells showed that Mcl-1 interacted with activator Bim, but not with Puma (Figure 4a ). Mcl-1 also interacted with Noxa. Immunoprecipitations with antiBcl-x L did not pull down these proteins (Figure 4b ). In contrast, Bim was pulled down by both anti-Mcl-1 and anti-Bcl-x L in H1975 cells, which depend on both Mcl-1 and Bcl-x L for survival (data not shown). These data indicated that H23 cells utilize Mcl-1 to neutralize the activity of activator BH3-only protein Bim for cell survival. It is likely that silencing Mcl-1 expression allows the release of these activators to induce apoptosis.
The activity of the apoptosis effectors Bak and Bax can be suppressed by the multidomain anti-apoptotic proteins such as Mcl-1 and Bcl-x L , as suggested by the indirect activation model (Willis et al., 2007) . We thus asked whether Mcl-1 and Bcl-x L interact with Bak and/ or Bax in H23 cells. Immunoprecipitations with antiMcl-1 showed that Mcl-1 interacted with Bak but not Bax (Figure 4a ). In contrast, immunoprecipitations with anti-Bcl-x L did not pull down either of these proteins (Figure 4b ). Our data thus indicated that Mcl-1 could also neutralize the activity of the effector protein Bak for cell survival.
Finally, to determine the roles of the Mcl-1 binding partners in Mcl-1 siRNA-induced cell death, we asked whether silencing these Mcl-1-binding proteins would rescue H23 cells from Mcl-1 knockdown. Silencing either Bim or Noxa rescued H23 cells from Mcl-1 knockdown to a lesser extent than silencing both Bim and Noxa together (Figure 4c ). Bim and Noxa siRNAs knocked down their respective target proteins effectively (Figure 4d ). These data further suggested that Mcl-1 binds and sequesters BH3-only proteins Bim and Noxa to resist cell death. We have also determined the role of apoptosis effector Bak and Bax in inducing cell death due to Mcl-1 knockdown. Silencing Bak rescued H23 cells from Mcl-1 knockdown to a much greater extent than by silencing Bax (data not shown). The partial rescue could be explained by incomplete knockdown of Bak in the experiment (data not shown). Our data Previous reports suggested that Mcl-1 has a role in modulating survival and sensitivity to diverse apoptotic stimuli, and overcoming drug resistance in NSCLC (Song et al., 2005; Wesarg et al., 2007) . In this study, we systematically evaluated the role of Mcl-1 by RNA interference and show that Mcl-1 is critical for survival in a subset of NSCLC cell lines, suggesting that different treatment regimes may be required for NSCLC subgroups. Various lines of evidence support our findings. First, Mcl-1-dependent NSCLC cell lines express high levels of MCL1 mRNA and protein, and low levels of BCL-xl mRNA and protein (Figures 1a and d) . Second, silencing Mcl-1 with siRNA killed these Mcl-1-dependent NSCLC cell lines effectively even after 2 days of transfection (Figure 1c) . Third, exogenous expression of a complementary DNA containing only the coding region of MCL1 rescued H23 cells from the toxicity of the 3 0 UTR-directed Mcl-1 siRNA (Figure 3a) . Fourth, we have shown by immunoprecipitations that Mcl-1 binds BH3-only proteins Bim and Noxa ( Figure 4a ). As expected, silencing Bim and Noxa almost completely rescued H23 cells from Mcl-1 knockdown (Figure 4c ). One potential explanation for the incomplete rescue is Mcl-1 could also bind effector Bak and prevents apoptosis (Leu et al., 2004; Zhai et al., 2008) . Indeed, we have also shown that Mcl-1 interacts with Bak directly (Figure 4a ). In addition, silencing Bak rescued H23 cells from Mcl-1 knockdown (data not shown). Taken together, these data indicate that a subset of NSCLC cell lines is Mcl-1 dependent and could be very valuable for studying the function of Mcl-1.
Mcl-1 overexpression has been reported in a variety of human hematopoietic cancers, lymphoid cancers and solid tumors (Akgul, 2009) . Although Mcl-1 has been shown to be a critical survival factor in multiple myeloma (Zhang et al., 2002) , Mcl-1 overexpression was generally believed to be a resistance mechanism to conventional cancer therapies in solid tumors (Akgul, 2009 (Figures 1a and d) . The combination of high Mcl-1 and low Bcl-x L expression might serve as a stratification marker for these patients. Indeed, the ratio of MCL1 to BCL-xl mRNA levels was 2-to 10-fold higher in Mcl-1-dependent cell lines (Figure 1d) .
In light of our findings, a working model of the two NSCLC subgroups is presented. The first subgroup of NSCLC expresses high levels of Mcl-1 relative to Bcl-x L . Mcl-1 could bind activators such as Bim and also inhibit the activity of effector such as Bak. When Mcl-1 is silenced, these activators and effectors are released and . Indeed, the viability of a portion of NSCLC lines was greatly reduced only when combining both Mcl-1 and Bcl-x L siRNAs (Figure 1c) . In this regard, it was shown that Mcl-1 could contribute to the overall resistance of SCLC cell lines and other cancer lines to a novel and potent Bcl-2 and Bcl-x L antagonist, ABT-737 Tahir et al., 2007; Tagscherer et al., 2008; Keuling et al., 2009) . Thus, combining agents that target Mcl-1 with ABT-737 might restore the apoptotic program in cells expressing high levels of Bcl-x L and Mcl-1 (Lin et al., 2007) . Our observations might have broader implications for patients with other cancer subtypes.
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